Literature DB >> 2518653

The cost of new drugs in the treatment of hypertension--the Australian experience.

W J Louis1.   

Abstract

The treatment of hypertension by costly new drugs such as the angiotensin converting enzyme inhibitors, means that careful monitoring of health care expenditure is essential. If drugs like simvastatin come to be widely used, costs will mount even more. New drugs cannot be used indiscriminately.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2518653     DOI： 10.1007/bf01869566

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN： 0920-3206            Impact factor:   3.727


  4 in total

1.  Conflict over drug policy in Australia.

Authors:  W J Louis
Journal:  BMJ       Date:  1989-02-25

Review 2.  Role of metabolic risk factors in cardiovascular prognosis of systemic hypertension.

Authors:  W J Louis; L G Howes; N Straznicki; H Krum; P Phillips; J Broadbear; J J McNeil
Journal:  Am J Cardiol       Date:  1990-05-02       Impact factor: 2.778

3.  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

4.  The Australian therapeutic trial in mild hypertension. Report by the Management Committee.

Authors: 
Journal:  Lancet       Date:  1980-06-14       Impact factor: 202.731
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.